TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06723223

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Traditional Peritoneal Equilibrium Test
Description: The first day started with a traditional PET consisting of a 240-minutes dwell with 2.3% glucose PD solutions. The intervention includes sampling of blood plasma (Na, K, glucose, creatinine, urea and albumin) and dialysate (Na, K, glucose, creatinine, urea and albumin).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Combined Peritoneal Equilibrium Test
Description: The PET test on the first day (Day 1) was followed by a short (60 min) combined PET with 4.25% glucose solution. On the second day (Day 2), the combined PET was repeated. The intervention includes sampling of blood plasma (Na, K, glucose, creatinine, urea and albumin) and dialysate (Na, K, glucose, creatinine, urea and albumin).
Study: NCT06722989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile-guided exercise
Description: Exercises for pregnant women in the SG will fall into moderate physical activity. They will be previously assessed by a perinatologist with a license to guide exercise during pregnancy. Each exercise will last 30 minutes, including initial warm-up exercises and final stretching exercises.~The recommended moderate activity for pregnant women is at least 150 minutes per week, achieved on at least three days. For pregnant women aged 29 years or less, this means within the limits of a heart rate of 125 to 146 beats/min. For pregnant women aged 30 years or more, it is within the limits of a heart rate of between 121 and 141 beats per minute. According to the Borg scale of perceived exertion from six to 20, moderate exercise is rated between 13 and 14, corresponding to the specified heart rate thresholds. The pregnant woman will rate her exercise on the Borg perceived exertion scale from six to 20. The recommended number of steps per day will be at least 6,000.
Study: NCT05696834

Intervention type: PROCEDURE
Intervention: Sclerotherapy With Adjuvant Bone Marrow Injection In Management of Aneurysmal Bone Cyst
Description: Sclerotherapy With Adjuvant Bone Marrow Injection In Management of Aneurysmal Bone Cyst
Study: NCT06722989

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unguided physical activity
Description: In this group, pregnant women will be physically active at their discretion.
Study: NCT06724042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISM5939
Description: ISM5939 tablets will be administered orally once daily (QD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISM5939
Description: ISM5939 tablets will be administered orally once daily (QD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISM5939
Description: ISM5939 tablets will be administered orally once daily (QD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered intravenously in combination with ISM5939 on day 1 during each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered intravenously in combination with ISM5939 on day 1 during each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered intravenously in combination with ISM5939 on day 1 during each cycle.
Study: NCT06724770

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resilience training intervention
Description: Training intervention on tools and strategies to strengthen the resilience of work teams in healthcare centres.
Study: NCT06724289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin 25 mg
Description: 25 mg psilocybin administered to each participant in single arm, open-label trial
Study: NCT06724744

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic training
Description: For twelve weeks, the women participate in aerobic training on cycle ergometer. Each session consists of 30-45 minutes of cycling at a moderate intensity, accompanied by a workout heart rate ranging from 65% to 75% of the maximal heart rate and ranging between 12 and 14 on the Borg rating of perceived exertion 20-point scale. After ten minutes of warm-up, every session ends with a brief 3-minute period of cool-down.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic training
Description: For twelve weeks, the women participate in aerobic training on cycle ergometer. Each session consists of 30-45 minutes of cycling at a moderate intensity, accompanied by a workout heart rate ranging from 65% to 75% of the maximal heart rate and ranging between 12 and 14 on the Borg rating of perceived exertion 20-point scale. After ten minutes of warm-up, every session ends with a brief 3-minute period of cool-down.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Diaphragm Release
Description: The participant is asked assume a supine position with relaxed limbs. The therapist should position themselves at the head of the participant and make manual contact with the pisiform, hypothenar region, and the last three fingers on both sides, underneath the seventh to tenth rib costal cartilages. The therapist's forearms should be aligned towards the participant's shoulders. During the inspiratory phase, the therapist gently pulled the points of contact with both hands in the direction of the head and slightly laterally, accompanying the elevation of the ribs. Therapist progressively increases the depth of their contact within the costal margin.
Study: NCT06722638

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of Virtual Reality Headset
Description: Virtual Reality Headsets will be used to augment pain and anxiety management during therapeutic LPs in children with acute lymphoblastic leukemia
Study: NCT06723795

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiologist evaluation
Description: The cardiology consultation will include the following: a structured interview (see Appendix A), physical examination, review of laboratory tests including HbA1c, lipid profile, BNP, ECG, and POCUS (point-of-care ultrasound) to assess heart contraction and valve function.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonologist evaluation
Description: optimize basic treatment, and recommend continued follow-up as needed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonologist evaluation
Description: optimize basic treatment, and recommend continued follow-up as needed.
Study: NCT06722729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KDT-3594
Description: Oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration
Study: NCT06722625

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of a blood pressure monitoring system with an integrated algorithm that supports the doctor's decision-making process
Description: Receiving remote care facilitated by a specialized informatic system to support the physician
Study: NCT06724419

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition education-based intervention
Description: The nutrition education-based intervention program will span 6 weeks, providing participants with comprehensive nutrition education based on dietary guidelines and comprising 8 topics , each lasting approximately 120 minutes. Its aim is to comprehensively promote participants' adoption of a healthy lifestyle through various educational formats.intervention and will each be provided with The PMS Management Booklet.
Study: NCT06756282

Intervention type: PROCEDURE
Intervention: Pacemaker and defibrillator
Description: only patients with pacemaker implantation will be evaluated in the study
Study: NCT06756880

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary function test
Description: Pulmonary function test results performed closest to the date of surgery and considered successful according to American Thoracic Society standards

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary function test
Description: Pulmonary function test results performed closest to the date of surgery and considered successful according to American Thoracic Society standards

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary function test
Description: Pulmonary function test results performed closest to the date of surgery and considered successful according to American Thoracic Society standards

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary function test
Description: Pulmonary function test results performed closest to the date of surgery and considered successful according to American Thoracic Society standards
Study: NCT06757270

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Second arm: Using aleovera for Prevention and Treatment of Chemotherapy-Induced Oral Mucositis
Description: Second arm : aleovera 3 times daily after brushing teeth
Study: NCT06757959

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Wet Needling
Description: This involve the use of needles to inject a local anesthetics into trigger points or areas of muscle tightness around the knee particularly in the quadriceps surrounding soft tissue implicated in patellofemoral pain syndrome .To reduce localized pain, release muscle tension and improve tissue function.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiotaping
Description: Application of kinesiotape around knee joint or quadricep following a specific technique aimed at reducing pain and improving joint stability . The tape is typically applied to encourge proper movement patterns , reducing swelling and provide sensory feedback to brain. Strengthening exercises : To strenghthen the quadriceps , gluteal muscles and other key stabilizing muscles of lower limbs. This is aimed at reducing the mechanical stress on the joint and improve overall function.
Study: NCT05680545

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sevoflurane vaporized in ECMO machines
Description: Sevoflurane will be directly vaporized into the ECMO machine through the sweep gas.
Study: NCT05993481

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood Pressure Measurement
Description: NIBP measurements will be recorded intraoperatively every 2.5 minutes for the group of 2.5 min. Blood pressure management or every 5 minutes for the other group of 5 min. Blood pressure management after providing randomization before the surgery. A calibrated and time-matched same type of standard anesthetic monitor will be used. The monitor will measure blood pressure and display the mean, systolic and diastolic values.~All blood pressure measurements will be discontinued before the PACU transfer. Data will be automatically downloaded from the monitor to a computer using a software interface program.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood Pressure Measurement
Description: NIBP measurements will be recorded intraoperatively every 2.5 minutes for the group of 2.5 min. Blood pressure management or every 5 minutes for the other group of 5 min. Blood pressure management after providing randomization before the surgery. A calibrated and time-matched same type of standard anesthetic monitor will be used. The monitor will measure blood pressure and display the mean, systolic and diastolic values.~All blood pressure measurements will be discontinued before the PACU transfer. Data will be automatically downloaded from the monitor to a computer using a software interface program.
Study: NCT04797572

Intervention type: DEVICE
Group type: OTHER
Intervention: Free Margin Cusp Sizer
Description: The free margin cusp sizer will be used during aortic valve repair and sparing procedures as a caliper to measure the aortic valve free margin length.
Study: NCT05792540

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine 20 mg
Description: Fluoxetine is a type of antidepressant known as a selective serotonin reuptake inhibitor (SSRI). It's often used to treat depression, and sometimes obsessive-compulsive disorder and bulimia. It works by increasing the levels of serotonin in the brain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine 20 mg
Description: Fluoxetine is a type of antidepressant known as a selective serotonin reuptake inhibitor (SSRI). It's often used to treat depression, and sometimes obsessive-compulsive disorder and bulimia. It works by increasing the levels of serotonin in the brain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine 20 mg
Description: Fluoxetine is a type of antidepressant known as a selective serotonin reuptake inhibitor (SSRI). It's often used to treat depression, and sometimes obsessive-compulsive disorder and bulimia. It works by increasing the levels of serotonin in the brain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg Tab
Description: Dapagliflozin (DAPA), a sodium-glucose co-transporter 2 inhibitor (SGLT2-I), has proven to be an effective hyperglycemic suppressor due to its role in inhibiting the reabsorption of 30-50% of the glucose filtered by the kidney, besides its role in the improvement of insulin resistance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 80mg
Description: Atorvastatin is a synthetic and lipophilic statin, a class of drugs used in the treatment of hypercholesterolemia
Study: NCT06304493

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Alarms
Description: The ON cohort patients will receive audible and visual signals from the InSee monitor attached to their incentive spirometer every 20 minutes and upon successfully reaching certain achievements.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alarms
Description: The ON cohort patients will receive audible and visual signals from the InSee monitor attached to their incentive spirometer every 20 minutes and upon successfully reaching certain achievements.
Study: NCT05628389

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational materials
Description: Patient educational materials to address insufficient knowledge about harms of tobacco use and cessation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational materials
Description: Patient educational materials to address insufficient knowledge about harms of tobacco use and cessation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational materials
Description: Patient educational materials to address insufficient knowledge about harms of tobacco use and cessation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone counseling
Description: Cessation counseling to address insufficient patient self-efficacy and motivation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone counseling
Description: Cessation counseling to address insufficient patient self-efficacy and motivation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy
Description: Nicotine patches to address nicotine withdrawal symptoms in patients.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Provider training
Description: Provider training to address insufficient knowledge and self-efficacy to deliver AAA/AAC to patients.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider training
Description: Provider training to address insufficient knowledge and self-efficacy to deliver AAA/AAC to patients.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider training
Description: Provider training to address insufficient knowledge and self-efficacy to deliver AAA/AAC to patients.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Electronic reminders
Description: Electronic reminders to address the lack of integration of AAA/AAC into practice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic reminders
Description: Electronic reminders to address the lack of integration of AAA/AAC into practice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic reminders
Description: Electronic reminders to address the lack of integration of AAA/AAC into practice.
Study: NCT06019156

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise video distribution of Metaverse
Description: Participants received a 10-minute exercise video each week with a load of about 4 to 8 metabolic equivalents of task (METs) in the metaverse space, for eight videos delivered to encourage exercise.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise video distribution of YouTube
Description: Participants view exercise videos with the same content as the metaverse group.
Study: NCT05161338

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SERUM PROGESTERONE LEVELS
Description: Determination of serum P4 levels On the day of embryo transfer scheduling (prior to the onset of exogenous progesterone administration) and on the embryo transfer day-.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SERUM OESTRADIOL LEVELS
Description: Determination of serum E2 levels On the day of embryo transfer scheduling (prior to the onset of exogenous progesterone administration) and on the embryo transfer day.
Study: NCT05436795

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abbott Panbio rapid antigen self-tests
Description: COVID-19 self-testing will be performed using investigational Abbott Panbio rapid antigen self-test kits that require self-sampled nasal swabs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COVIDSmart CARE! app
Description: Guided by the application that connects, educates, and communicates a digital, contactless open access strategy, participants will have the opportunity to self-test and assess their risk level of COVID-19 infection, as well as the option to refer their close contacts to testing for those who are COVID-19 positive, through the study platform.
Study: NCT04862351

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training for TechCR
Description: 3 times of supervised exercise training at the centre-based, outpatient cardiac rehabilitation clinic
Study: NCT05590611

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Intervention with Brown Bread
Description: The participants in this group will be asked to replace all their habitual bread intake by standard brown bread. The duration of the study for each participant is 4 weeks. Apart from the change in type of bread, participants will maintain their habitual diet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention with Sourdough Bread
Description: The participants in thisgroup will be asked to replace all their habitual bread intake by wholemeal sourdough bread. The duration of the study for each participant is 4 weeks. Apart from the change in type of bread, participants will maintain their habitual diet.
Study: NCT04862351

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: audio/video conference
Description: weekly audio/video conference

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational video
Description: weekly for 6 weeks, duration of video about 10-15 minutes

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Daily log
Description: daily dietary and exercise log

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily log
Description: daily dietary and exercise log

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: exercise training for centre-based
Description: 6 times of supervised exercise training
Study: NCT05578664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab injection plus metastasis directed treatment (surgery or RT)
Description: Pembrolizumab 400 mg will be administered as a 30 minute IV infusion every 6 weeks for a total of 9 cycles (one year of therapy) and metastasis directed treatment (surgery or RT) from day 21 of cycle 1 to day 42 of cycle 1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tumor resection or RT
Description: Tumor resection or RT will be applied within 42 days from randomization.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tumor resection or RT
Description: Tumor resection or RT will be applied within 42 days from randomization.
Study: NCT04272320

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: Ultrasound-guided Transversalis Fascia Plane Block with 0.5 ml/kg %0.25 bupivacaine
Study: NCT05486988

Intervention type: DRUG
Intervention: Immunotherapy
Description: PD-1/PD-L1 inhibitors
Study: NCT04691570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANX005
Description: ANX005 is provided as a solution for IV infusion
Study: NCT04643158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1402
Description: Randomised participants will receive oral inhalation of AZD1402, via DPI.
Study: NCT05486988

Intervention type: DRUG
Intervention: Immunotherapy
Description: PD-1/PD-L1 inhibitors

Intervention type: DRUG
Intervention: Chemotherapeutic Agent
Description: 2 cycles

Intervention type: DRUG
Intervention: Chemotherapy
Description: 4\~6 cycles
Study: NCT04881149

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TempSure treatment
Description: Self-controlled, single-arm study using the TempSure device.
Study: NCT06436612

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Image and Computed Tomography-Guided Stereotactic Body Radiation Therapy
Description: stereotactic body radiation therapy (SBRT) administered over 5 days x 5.0 - 6.0 Gy for patients with abdominopelvic sarcomas.
Study: NCT05333549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istradefylline medication
Description: 2 weeks on istradefylline 20mg daily, 2 weeks on istradefylline 40mg with the ability to adjust other antiparkinsonian medications, and 22 weeks on istradefylline 40mg and stable antiparkinsonian medications
Study: NCT06580756

Intervention type: OTHER
Intervention: Short training program
Description: Training in the early identification of addictive disorders in primary care
Study: NCT06031558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-5007
Description: a RET selective Inhibitor
Study: NCT06331169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Trastuzumab deruxtecan is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor.
Study: NCT05765500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Gonadotropin-releasing hormone (GnRH) antagonist, oral tablet taken 1x daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide
Description: Gonadotropin-releasing hormone (GnRH) antagonist, intramuscular injection 1x every 3 months.